NEW YORK (GenomeWeb News) – Israeli plant genomics firm Evogene today reported a 5 percent increase in revenues for its third quarter.

Evogene said that revenues for the three months ended Sept. 30 totaled $4.2 million, up from $4.0 million a year ago. Its comprehensive loss for the period rose to $2.3 million, or $.06 per share, from a comprehensive loss of $1.0 million, or $.03 per share, in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.